279 related articles for article (PubMed ID: 28901731)
1. Response to combination of mycophenolate mofetil, cyclosporin A and corticosteroid treatment in lupus nephritis patients with persistent proteinuria.
Kasitanon N; Boripatkosol P; Louthrenoo W
Int J Rheum Dis; 2018 Jan; 21(1):200-207. PubMed ID: 28901731
[TBL] [Abstract][Full Text] [Related]
2. Multitarget therapy of mycophenolate mofetil and cyclosporine A for induction treatment of refractory lupus nephritis.
Jesus D; Rodrigues M; da Silva JAP; Inês L
Lupus; 2018 Jul; 27(8):1358-1362. PubMed ID: 29448882
[TBL] [Abstract][Full Text] [Related]
3. Comparison of disease activity between tacrolimus and mycophenolate mofetil in lupus nephritis: a randomized controlled trial.
Kamanamool N; Ingsathit A; Rattanasiri S; Ngamjanyaporn P; Kasitanont N; Chawanasuntorapoj R; Pichaiwong W; Anutrakulchai S; Sangthawan P; Ophascharoensuk V; Avihingsanon Y; Sumethkul V
Lupus; 2018 Apr; 27(4):647-656. PubMed ID: 29105558
[TBL] [Abstract][Full Text] [Related]
4. Long-term outcomes with multi-targeted immunosuppressive protocol in children with severe proliferative lupus nephritis.
Aragon E; Resontoc LP; Chan YH; Lau YW; Tan PH; Loh HL; Ng KH; Yap HK
Lupus; 2016 Apr; 25(4):399-406. PubMed ID: 26537422
[TBL] [Abstract][Full Text] [Related]
5. Treatment of lupus nephritis by mycophenolate mofetil.
Rabrenović V; Poskurica M; Kovacević Z; Nesić V; Savin M; Mitić B; Dimković N; Cucković C; Vujić D; Pljesa S; Perunicić-Peković G; Curić S; Mitić I; Ratković M; Marinković J; Jovanović D
Kidney Blood Press Res; 2010; 33(4):297-303. PubMed ID: 20664209
[TBL] [Abstract][Full Text] [Related]
6. Outcome and predictors of renal survival in patients with lupus nephritis: Comparison between cyclophosphamide and mycophenolate mofetil.
Joo YB; Kang YM; Kim HA; Suh CH; Kim TJ; Park YW; Lee J; Lee JH; Yoo DH; Bae SC; Lee HS; Bang SY
Int J Rheum Dis; 2018 May; 21(5):1031-1039. PubMed ID: 29611341
[TBL] [Abstract][Full Text] [Related]
7. Combination therapy of rituximab and mycophenolate mofetil in childhood lupus nephritis.
Hogan J; Godron A; Baudouin V; Kwon T; Harambat J; Deschênes G; Niel O
Pediatr Nephrol; 2018 Jan; 33(1):111-116. PubMed ID: 28780657
[TBL] [Abstract][Full Text] [Related]
8. Clinical manifestations, immunological features and prognosis of Chinese pediatric systemic lupus erythematosus: A single-center study.
Zhang CX; Cai L; Zhou ZY; Mao YY; Huang H; Yin L; Chen TX; Zhou W
Int J Rheum Dis; 2019 Jun; 22(6):1070-1076. PubMed ID: 30957986
[TBL] [Abstract][Full Text] [Related]
9. Outcomes of multitarget therapy using mycophenolate mofetil and tacrolimus for refractory or relapsing lupus nephritis.
Choi CB; Won S; Bae SC
Lupus; 2018 May; 27(6):1007-1011. PubMed ID: 29448881
[TBL] [Abstract][Full Text] [Related]
10. Induction therapies for class IV lupus nephritis with non-inflammatory necrotizing vasculopathy: mycophenolate mofetil or intravenous cyclophosphamide.
Wang J; Hu W; Xie H; Zhang H; Chen H; Zeng C; Liu Z; Li L
Lupus; 2007; 16(9):707-12. PubMed ID: 17728363
[TBL] [Abstract][Full Text] [Related]
11. Comparison of Lupus Nephritis Induction Treatments in a Hispanic Population: A Single-center Cohort Analysis.
Mejía-Vilet JM; Arreola-Guerra JM; Córdova-Sánchez BM; Morales-Buenrostro LE; Uribe-Uribe NO; Correa-Rotter R
J Rheumatol; 2015 Nov; 42(11):2082-91. PubMed ID: 26373566
[TBL] [Abstract][Full Text] [Related]
12. Induction therapy for membranous lupus nephritis: a systematic review and network meta-analysis.
Tang KT; Tseng CH; Hsieh TY; Chen DY
Int J Rheum Dis; 2018 Jun; 21(6):1163-1172. PubMed ID: 29879319
[TBL] [Abstract][Full Text] [Related]
13. Randomized controlled trial of pulse intravenous cyclophosphamide versus mycophenolate mofetil in the induction therapy of proliferative lupus nephritis.
Ong LM; Hooi LS; Lim TO; Goh BL; Ahmad G; Ghazalli R; Teo SM; Wong HS; Tan SY; Shaariah W; Tan CC; Morad Z
Nephrology (Carlton); 2005 Oct; 10(5):504-10. PubMed ID: 16221103
[TBL] [Abstract][Full Text] [Related]
14. Low-dose cyclosporine for active lupus nephritis: a dose titration approach.
Sumethkul K; Kitumnuaypong T; Angthararak S; Pichaiwong W
Clin Rheumatol; 2019 Aug; 38(8):2151-2159. PubMed ID: 30937637
[TBL] [Abstract][Full Text] [Related]
15. Combined low-dose mycophenolate mofetil and tacrolimus for lupus nephritis with suboptimal response to standard therapy: a 12-month prospective study.
Mok CC; To CH; Yu KL; Ho LY
Lupus; 2013 Oct; 22(11):1135-41. PubMed ID: 23995863
[TBL] [Abstract][Full Text] [Related]
16. The safety and efficacy of MMF in lupus nephritis: a pilot study.
Kingdon EJ; McLean AG; Psimenou E; Davenport A; Powis SH; Sweny P; Burns A
Lupus; 2001; 10(9):606-11. PubMed ID: 11678448
[TBL] [Abstract][Full Text] [Related]
17. Comparison of low-dose intravenous cyclophosphamide with oral mycophenolate mofetil in the treatment of lupus nephritis.
Rathi M; Goyal A; Jaryal A; Sharma A; Gupta PK; Ramachandran R; Kumar V; Kohli HS; Sakhuja V; Jha V; Gupta KL
Kidney Int; 2016 Jan; 89(1):235-42. PubMed ID: 26489028
[TBL] [Abstract][Full Text] [Related]
18. Tacrolimus versus mycophenolate mofetil for induction therapy of lupus nephritis: a randomised controlled trial and long-term follow-up.
Mok CC; Ying KY; Yim CW; Siu YP; Tong KH; To CH; Ng WL
Ann Rheum Dis; 2016 Jan; 75(1):30-6. PubMed ID: 25550339
[TBL] [Abstract][Full Text] [Related]
19. Multicentric study comparing cyclosporine, mycophenolate mofetil and azathioprine in the maintenance therapy of lupus nephritis: 8 years follow up.
Argolini LM; Frontini G; Elefante E; Saccon F; Binda V; Tani C; Scotti I; Carli L; Gatto M; Esposito C; Gerosa M; Caporali R; Doria A; Messa P; Mosca M; Moroni G
J Nephrol; 2021 Apr; 34(2):389-398. PubMed ID: 32462476
[TBL] [Abstract][Full Text] [Related]
20. Efficacy of enteric-coated mycophenolate sodium in patients with active lupus nephritis.
Mak SK; Lo KY; Lo MW; Chan SF; Tong GM; Wong PN; Wong AK
Nephrology (Carlton); 2008 Jun; 13(4):331-6. PubMed ID: 18476916
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
